Oct. 12 at 8:23 PM
$OSTX $SPY $DJT $PFI $MRK
Strong conviction play here in Bio Pharma:
'OSTX posts 75% survival in trial, aims for global OST-HER2 approvals by 2026
OST-HER2 shows promise in bone cancer; OSTX eyes FDA and EMA submissions
OS Therapies boosts survival rates, pushing OST-HER2 to global regulatory doors
OSTX rises on strong osteosarcoma data, sets December MAA filing timeline
OSTX delivers breakthrough in cancer trial, charts path to global market launch
Future Milestones and Market Implications for OSTX
OSTX planned to discuss the latest trial outcomes and regulatory plans in a conference call on October 13, 2025. The event, scheduled for 8:30 a.m. ET, would provide updates on OST-HER2’s development and pathway to market. Access details for the webcast were expected on the company’s website hours before the call.'
Ignore the chaos and buy this gem. You can thank me on our yachts.
https://parameter.io/os-therapies-inc-ostx-stock-rises-on-breakthrough-phase-2b-survival-data-showcasing-strong-efficacy-in-metastatic-osteosarcoma/